Vivani Medical, Inc. (VANI)
NASDAQ: VANI · Real-Time Price · USD
1.260
-0.030 (-2.33%)
Nov 4, 2024, 4:00 PM EST - Market closed

Company Description

Vivani Medical, Inc., a preclinical stage biopharmaceutical company, engages in the development of miniaturized and subdermal implants that treat chronic diseases.

The company uses its NanoPortal implant technology to develop and potentially commercialize drug implant candidates in the treatment of chronic disease, medication non-adherence.

Its pipeline includes NPM-115, a high-dose exenatide implant candidate is in preclinical stage development for the treatment of chronic weight management in patients with obesity or overweight; NPM-119, an exenatide implant candidate is in preclinical stage development for the treatment of patients with type 2 diabetes; NPM-139, a miniature, subdermal GLP-1 implant in development for chronic weight management; and OKV-119, an exenatide implant is under development for metabolic diseases in cats including for the treatment of obesity and diabetes.

The company is headquartered in Alameda, California.

Vivani Medical, Inc.
Vivani Medical logo
Country United States
Founded 1998
IPO Date Nov 19, 2014
Industry Biotechnology
Sector Healthcare
Employees 44
CEO Adam Mendelsohn

Contact Details

Address:
1350 South Loop Road
Alameda, California 94502
United States
Phone 415 506 8462
Website vivani.com

Stock Details

Ticker Symbol VANI
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
CIK Code 0001266806
CUSIP Number 92854B109
ISIN Number US92854B1098
SIC Code 3845

Key Executives

Name Position
Adam Mendelsohn Ph.D. Co-Founder, Chief Executive Officer and Director
Truc Le M.B.A. Chief Operations Officer
Dr. Lisa E. Porter M.D. Chief Medical Officer
Donald Dwyer M.B.A. Chief Business Officer and Corporate Secretary

Latest SEC Filings

Date Type Title
Oct 22, 2024 8-K Current Report
Sep 26, 2024 8-K Current Report
Sep 23, 2024 8-K Current Report
Sep 4, 2024 8-K Current Report
Aug 13, 2024 8-K Current Report
Aug 13, 2024 10-Q Quarterly Report
Jul 11, 2024 8-K Current Report
Jun 28, 2024 8-K Current Report
Jun 13, 2024 8-K Current Report
May 13, 2024 10-Q Quarterly Report